Definium Therapeutics, Inc. (DFTX)

US — Healthcare Sector
Peers: URGN  BBOT  TNGX  ANAB  RZLT  XNCR  NRIX  FTRE  KOD  SVRA 

Automate Your Wheel Strategy on DFTX

With Tiblio's Option Bot, you can configure your own wheel strategy including DFTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
DFTX
Published: February 26, 2026 by: Seeking Alpha
Sentiment: Neutral

Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript

Read More
image for news Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics Announces New Employee Inducement Grants
DFTX
Published: February 02, 2026 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 28,640 common shares of the Company (the “Options”) with.

Read More
image for news Definium Therapeutics Announces New Employee Inducement Grants

About Definium Therapeutics, Inc. (DFTX)

  • IPO Date 2016-11-15
  • Website https://definiumtx.com
  • Industry Biotechnology
  • CEO Robert Barrow
  • Employees 74
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.